4.7 Review

MRI features of benign multiple sclerosis Toward a new definition of this disease phenotype

期刊

NEUROLOGY
卷 72, 期 19, 页码 1693-1701

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181a55feb

关键词

-

资金

  1. Dutch MS Research Foundation [06-538c]
  2. Fondazione Italiana Sclerosi Multipla [2005/R/9]

向作者/读者索取更多资源

It is well known that the current classification of patients with benign multiple sclerosis (BMS), i.e., those with absent or minimal locomotor disability several years after disease onset, suffers from not having any prognostic value for the subsequent evolution of multiple sclerosis (MS). The identification of markers predictive of the longer-term course of MS will help define BMS more reliably and would allow better counseling of patients, particularly when advising on the initiation of a disease-modifying treatment. MRI-based evidence suggests that there are three potential, but not mutually exclusive, explanations for the scarce clinical impact of BMS: 1) the paucity of tissue damage within and outside MS lesions; 2) the relative sparing of clinically eloquent regions; and 3) the presence of effective compensatory mechanisms. In addition, the results of correlative MRI/neuropsychology studies underpin the need for a new definition of BMS, which should consider the maintenance of a normal cognitive profile as an additional criterion. Neurology (c) 2009;72:1693-1701

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Multicenter data harmonization for regional brain atrophy and application in multiple sclerosis

Elisabetta Pagani, Loredana Storelli, Patrizia Pantano, Nikolaos Petsas, Gioacchino Tedeschi, Antonio Gallo, Nicola De Stefano, Marco Battaglini, Maria A. Rocca, Massimo Filippi

Summary: In patients with multiple sclerosis, the determination of brain atrophy in specific regions is clinically relevant. However, analyzing large datasets is challenging due to the increased variability in multicenter data. This study compared different methods to correct for center effects and investigated regional gray matter volume in patients with relapsing-remitting multiple sclerosis using a large multicenter dataset. The results showed that harmonization based on subsampling effectively reduced the residuals of the statistical model applied, and the multicenter results were more robust compared to findings from single-center analysis, highlighting the importance of data repositories from multiple centers.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Cerebellar alterations in Parkinson's disease with postural instability and gait disorders

Andrea Gardoni, Federica Agosta, Elisabetta Sarasso, Silvia Basaia, Elisa Canu, Michela Leocadi, Veronica Castelnovo, Andrea Tettamanti, Maria Antonietta Volonte, Massimo Filippi

Summary: This study aimed to assess cerebellar atrophy and activity alterations during functional MRI (fMRI) gait-simulating motor- and dual-tasks in Parkinson's disease patients with postural instability and gait disorders (PD-PIGD). The results showed that PD-PIGD patients had reduced volumes of cerebellar motor and non-motor areas and increased activity of cognitive areas during fMRI tasks. These findings suggest that the increased activity of non-motor cerebellar areas may be a compensatory mechanism in response to cerebellar motor dysfunction in PD-PIGD.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

Xavier Montalban, Daniel Wallace, Mark C. Genovese, Davorka Tomic, Dana Parsons-Rich, Claire Le Bolay, Amy H. Kao, Hans Guehring

Summary: This study provides an integrated safety analysis of the Bruton's tyrosine kinase inhibitor Evobrutinib in multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus trials. The results demonstrate that Evobrutinib is generally well tolerated across indications.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Review Clinical Neurology

The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact

Lyduine E. Collij, Gill Farrar, David Vallez Garcia, Ilona Bader, Mahnaz Shekari, Luigi Lorenzini, Hugh Pemberton, Daniele Altomare, Sandra Pla, Mery Loor, Pawel Markiewicz, Maqsood Yaqub, Christopher Buckley, Giovanni B. Frisoni, Agneta Nordberg, Pierre Payoux, Andrew Stephens, Rossella Gismondi, Pieter Jelle Visser, Lisa Ford, Mark Schmidt, Cindy Birck, Jean Georges, Anja Mett, Zuzana Walker, Merce Boada, Alexander Drzezga, Rik Vandenberghe, Bernard Hanseeuw, Frank Jessen, Michael Scholl, Craig Ritchie, Isadora Lopes Alves, Juan Domingo Gispert, Frederik Barkhof, AMYPAD Consortium

Summary: Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) consortium aims to provide evidence on the clinical utility and cost-effectiveness of Positron Emission Tomography (PET) imaging in AD diagnosis and support clinical trial design. AMYPAD has contributed significantly to understanding of amyloid deposition in the brain and improving measurement methodology. Future steps include integrating and curating available clinical data for wider scientific access.

FRONTIERS IN NEUROLOGY (2023)

Article Clinical Neurology

Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets A MAGNIFY-MS Substudy

Heinz Wiendl, Klaus Schmierer, Suzanne Hodgkinson, Tobias Derfuss, Andrew Chan, Finn Sellebjerg, Anat Achiron, Xavier Montalban, Alexandre Prat, Nicola De Stefano, Frederik Barkhof, Letizia Leocani, Patrick Vermersch, Anita Chudecka, Claire Mwape, Kristina H. Holmberg, Ursula Boschert, Sanjeev Roy, MAGNIFY-MS Study Grp

Summary: Cladribine tablets cause a reduction in lymphocytes, with a predominant effect on B-cell and T-cell counts. The MAGNIFY-MS substudy reports the dynamic changes on multiple peripheral blood mononuclear cell (PBMC) subtypes and immunoglobulin (Ig) levels over 12 months after the first course of cladribine tablets in patients with highly active relapsing multiple sclerosis (MS).

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Review Clinical Neurology

Longitudinal amyloid and tau PET imaging in Alzheimer's disease: A systematic review of methodologies and factors affecting quantification

Ariane G. Bollack, Hugh G. E. Pemberton, Lyduine E. Collij, Pawel M. Markiewicz, David M. Cash, Gill Farrar, Frederik Barkhof

Summary: This review summarizes the current design and methodologies of longitudinal PET studies, utilizing positron emission tomography to quantify amyloid and tau pathology. The intrinsic variability of AD protein load over time and technical factors contributing to PET measurement uncertainty are detailed. Suggestions for mitigating these factors, including leveraging shared information between serial scans, are provided.

ALZHEIMERS & DEMENTIA (2023)

Article Clinical Neurology

Unraveling the heterogeneous pathological substrates of relapse-onset multiple sclerosis: a multiparametric voxel-wise 3 T MRI study

Monica Margoni, Elisabetta Pagani, Paolo Preziosa, Mor Gueye, Matteo Azzimonti, Maria A. Rocca, Massimo Filippi

Summary: This study used multimodal MRI to investigate the regional distribution of different pathological processes in the brain white and gray matter of relapse-onset multiple sclerosis (MS) patients. The results showed that compared to healthy controls, relapsing-remitting MS (RRMS) patients exhibited white matter, deep gray matter, and cortical atrophy, as well as significantly lower MTR and T1w/T2w ratio in periventricular and infratentorial white matter, deep gray matter, and several cortical areas. Secondary progressive MS (SPMS) patients showed more severe deep gray matter and widespread cortical atrophy, lower MTR of periventricular white matter, deep gray matter, and cerebellum, lower T1w/T2w ratio of fronto-temporal white matter regions, lower ICV_f of some fronto-tempo-occipital white matter and cortical areas, and increased QSM and T1w/T2w ratio in the pallidum.

JOURNAL OF NEUROLOGY (2023)

Article Neurosciences

Transferability of Alzheimer?s disease progression subtypes to an independent population cohort

Hanyi Chen, Alexandra Young, Neil P. Oxtoby, Frederik Barkhof, Daniel C. Alexander, Andre Altmann

Summary: This study examines the generalisability of data-driven Alzheimer's disease (AD) progression models using the SuStaIn algorithm. The results show consistent subtypes of atrophy in both datasets and high consistency in individuals' subtypes and stage assignments. The study also reveals associations between AD atrophy subtypes and risk factors.

NEUROIMAGE (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection

Piet M. Bouman, Samantha Noteboom, Fernando A. Nobrega Santos, Erin S. Beck, Gregory Bliault, Marco Castellaro, Massimiliano Calabrese, Declan T. Chard, Paul Eichinger, Massimo Filippi, Matilde Inglese, Caterina Lapucci, Andrzej Marciniak, Bastiaan Moraal, Alfredo Morales Pinzon, Mark Muehlau, Paolo Preziosa, Daniel S. Reich, Maria A. Rocca, MennoM. Schoonheim, Jos W. R. Twisk, Benedict Wiestler, Laura E. Jonkman, Charles R. G. Guttmann, Jeroen J. G. Geurts, Martijn D. Steenwijk

Summary: This study evaluated the detection ability of artificial intelligence-generated double inversion recovery (DIR) and phase-sensitive inversion recovery (PSIR) images for cortical and juxtacortical multiple sclerosis lesions in a multicenter setting, compared with MRI-acquired images. The results showed that the AI-generated images performed well compared to the MRI-acquired images and demonstrated good reliability in a multicenter setting, with good interpretative agreement between readers and centers.

RADIOLOGY (2023)

Article Clinical Neurology

A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis

Xavier Montalban, Daniel Wallace, Mark C. Genovese, Davorka Tomic, Dana Parsons-Rich, Claire Le Bolay, Amy H. Kao, Hans Guehring

Summary: This summary explains the findings from a recent investigation that combined the results of over 1000 people from three clinical studies to understand the safety of evobrutinib. The medication was found to be well-tolerated by participants in all three studies, with similar side effects to those reported by participants taking the placebo. The results suggest that further research into using evobrutinib in MS is promising.

NEURODEGENERATIVE DISEASE MANAGEMENT (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Global and Regional Deep Learning Models for Multiple Sclerosis Stratification From MRI

Llucia Coll, Deborah Pareto, Pere Carbonell-Mirabent, Alvaro Cobo-Calvo, Georgina Arrambide, Angela Vidal-Jordana, Manuel Comabella, Joaquinprime Castillo, Breogan Rodriguez-Acevedo, Ana Zabalza, Ingrid Galan, Luciana Midaglia, Carlos Nos, Cristina Auger, Manel Alberich, Jordi Rio, Jaume Sastre-Garriga, Arnau Oliver, Xavier Montalban, Alex Rovira, Mar Tintore, Xavier Llado, Carmen Tur

Summary: This study compares the effect of different input strategies on the performance of predictive models for multiple sclerosis prognosis. The results show that both the global approach and specific-tissue strategies perform well in the internal dataset and achieve high accuracy in external validation.

JOURNAL OF MAGNETIC RESONANCE IMAGING (2023)

Article Clinical Neurology

Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine

Maria A. Rocca, Paola Valsasina, Maria Teresa Lamanna, Bruno Colombo, Vittorio Martinelli, Massimo Filippi

Summary: This study aimed to investigate the pathogenesis of fatigue in multiple sclerosis (MS) patients. The researchers found that there were modifications in fatigue severity and resting state functional connectivity (RS FC) in monoaminergic networks after different symptomatic treatments. These modifications involved dopamine, noradrenaline, and serotonin-related RS FC.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment

Damiano Mistri, Nicolo Tedone, Diana Biondi, Carmen Vizzino, Elisabetta Pagani, Maria A. Rocca, Massimo Filippi

Summary: This study identified five cognitive phenotypes with varying degrees of impairment in multiple sclerosis (MS) patients and described their characteristics. The findings suggest potential variations in the neural substrates of dysfunction throughout disease stages in MS.

JOURNAL OF NEUROLOGY (2023)

Meeting Abstract Clinical Neurology

Outcomes of COVID-19 in Ofatumumab-treated RMS Patients: Data from the ALITHIOS open label extension study

H. Wiend, A. Cross, S. Delgado, M. Habek, N. Khachanova, B. Ward, B. Cree, N. Totolyan, L. Mancione, R. Sullivan, R. Zielman, X. Hu, A. Gupta, X. Montalban, K. Winthrop

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Safety and efficacy with alemtuzumab over 13?years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Alasdair J. Coles, Anat Achiron, Anthony Traboulsee, Barry A. Singer, Carlo Pozzilli, Celia Oreja-Guevara, Gavin Giovannoni, Giancarlo Comi, Mark S. Freedman, Tjalf Ziemssen, Debora Shiota, Andreea M. Rawlings, Alana T. Wong, Magdalena Chirieac, Xavier Montalban

Summary: The safety risks associated with alemtuzumab treatment decreased over time, and the clinical benefits were maintained for 11-13 years, with most patients not requiring additional courses.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2023)

暂无数据